Please assess the completion status of the following clinical trial:

Trial Title: Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Established diagnosis of New York Heart Association (NYHA) Class II or Class III heart failure (left ventricular ejection fraction ≤40% due to either ischemic or non-ischemic etiology) with reduced systolic function for at least 16 weeks prior to enrollment~2. No change in diuretic management for at least 1 week prior to enrollment~3. Brain natriuretic peptide (BNP) ≥100 pg/mL and/or N-terminal pro b-type natriuretic peptide (NTproBNP) ≥ 400 pg/mL at enrollment~Exclusion Criteria:~1. History of type 1 diabetes~2. Estimated glomerular filtration rate (eGFR) \< 30 at enrollment~3. Hospitalization for heart failure within the 30 days prior to enrollment~4. Admission for an acute coronary syndrome (ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, or unstable angina), percutaneous coronary intervention, or cardiac surgery within the 30 days prior to enrollment~5. Admission for cardiac resynchronization therapy (CRT) within 90 days prior to the screening visit~6. Planned cardiovascular revascularization (percutaneous intervention or surgical) or major cardiac surgery (coronary artery bypass grafting, valve replacement, ventricular assist device, cardiac transplantation, or any other surgery requiring thoracotomy) within the 90 days after enrollment~7. Patients who are volume depleted based upon physical examination at the time of screening or randomization

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 119 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin (Type: ACTIVE_COMPARATOR): Dapagliflozin 10 mg daily
- Dapagliflozin matching placebo (Type: PLACEBO_COMPARATOR): Dapagliflozin matching placebo 10 mg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).